Phosphorescent Cationic Heterodinuclear IrIII /MI Complexes (M=CuI , AuI ) with a Hybrid Janus-Type N-Heterocyclic Carbene Bridge.

A novel class of phosphorescent cationic heterobimetallic IrIII /MI complexes, where MI =CuI (4) and AuI (5), is reported. The two metal centers are connected by the hybrid bridging 1,3-dimesityl-5-acetylimidazol-2-ylidene-4-olate (IMesAcac) ligand that combines both a chelating acetylacetonato-like and a monodentate N-heterocyclic carbene site coordinated onto an IrIII and a MI center, respectively. Complexes 4 and 5 have been prepared straightforwardly by a stepwise site-selective metalation with the zwitterionic [(IPr)MI (IMesAcac)] metalloproligand (IPr=1,3-(2,6-diisopropylphenyl)-2H-imidazol-2-ylidene) and they have been fully characterized by spectroscopic, electrochemical, and computational investigation. Complexes 4 and 5 display intense red emission arising from a low-energy excited state that is located onto the "Ir(C^N)" moiety featuring an admixed triplet ligand-centered/metal-to-ligand charge transfer (3 IL/1 MLCT) character. Comparison with the benchmark mononuclear complexes reveals negligible electronic coupling between the two distal metal centers at the electronic ground state. The bimetallic systems display enhanced photophysical properties in comparison with the parental congeners. Noteworthy, similar non-radiative rate constants have been determined along with a two-fold increase of radiative rate, yielding brightly red-emitting cyclometalating IrIII complexes. This finding is ascribed to the increased MLCT character of the emitting state in complexes 4 and 5 due to the smaller energy gap between the 3 IL and 1 MLCT manifolds, which mix via spin-orbit coupling.

An N-heterocyclic carbene iridium(III) complex as a potent anti-cancer stem cell therapeutic.

Cancer stem cells (CSCs) represent a difficult to treat cellular niche within tumours due to their unique characteristics, which give them a high propensity for resistance to classical anti-cancer treatments and the ability to repopulate the tumour mass. An attribute that may be implicated in the high rates of recurrence of certain tumours. However, other characteristics specific to these cells, such as their high dependence on mitochondria, may be exploited for the development of new therapeutic agents that are effective against the niche. As such, a previously described phosphorescent N-heterocyclic carbene iridium(III) compound which showed a high level of cytotoxicity against classical tumour cell lines with mitochondria-specific effects was studied for its potential against CSCs. The results showed a significantly higher level of activity against several CSC lines compared to non-CSCs. Mitochondrial localisation and superoxide production were confirmed. Although the cell death involved caspase activation, their role in cell death was not definitive, with a potential implication of other, non-apoptotic pathways shown. A cytostatic effect of the compound was also displayed at low mortality doses. This study thus provides important insights into the mechanisms and the potential for this class of molecule in the domain of anti-CSC therapeutics.

Red-emitting neutral rhenium(i) complexes bearing a pyridyl pyridoannelated N-heterocyclic carbene.

Two novel rhenium(i) tricarbonyl complexes of general formula fac-[Re(N^C:)(CO)3X] are herein presented, where N^C: is the pyridoannelated N-heterocyclic carbene (NHC) arising from 2-(2-pyridinyl)imidazo[1,5-a]pyridinium hexafluorophosphate proligand, namely [pyipy]PF6, and X being Cl and Br. The synthetic pathway is a one-pot reaction that starts from the azolium salt as the NHC source and [Re(CO)5X] to yield the desired charge-neutral fac-[Re(pyipy)(CO)3X] complexes (1-2). Both complexes were thoroughly characterized by spectroscopic, electrochemical, theoretical investigation as well as X-ray diffraction analysis. They display a rather similar electronic absorption spectrum in dilute CH2Cl2 solution, which is characterized by a broad profile extending into the blue region. This lowest-lying absorption band is attributed to a transition with admixed metal-to-ligand charge transfer and intraligand charge transfer (1MLCT/1ILCT) character. Degassed samples of the complexes display moderate (Φ≈ 1.5%) and long-lived (τ = 12.8-13.4 µs) red photoluminescence with highly structured profile independent of the nature of the ancillary halogen ligand and little sensitivity to the solvent polarity, highlighting the markedly different nature of the emitting excited state in comparison with the lowest-lying absorption. Indeed, photoluminescence is ascribed to a long-lived excited state with metal-perturbed triplet ligand-centred (3LC) character as supported by both experimental and density functional theory (DFT) investigations.